In the competitive field of Form Specific Drugs, companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top opposing and opposed companies, and the most recent patents getting opposed. Stay informed on the latest developments in Form Specific Drugs technology and learn how to protect your intellectual property.

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the Form Specific Drugs industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the Form Specific Drugs industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Patent NumberTitleApplicantOpposition DateOpposition Name

Get alerts on new patent oppositions in the Form Specific Drugs industry

EP4159204Novel Pharmaceutical CompositionNOVARTIS AGNov 14, 2024GENERICS (U.K.) LIMITED
EP4159205Novel Pharmaceutical CompositionNOVARTIS AGNov 14, 2024BRAND MURRAY FULLER LLP
EP4159204Novel Pharmaceutical CompositionNOVARTIS AGNov 13, 2024TEVA PHARMACEUTICAL INDUSTRIES, LTD.
EP4159205Novel Pharmaceutical CompositionNOVARTIS AGNov 13, 2024TEVA PHARMACEUTICAL INDUSTRIES LTD
EP4159204Novel Pharmaceutical CompositionNOVARTIS AGNov 11, 2024HAMM&WITTKOPP PATENTANWALTE PARTMBB
EP4159205Novel Pharmaceutical CompositionNOVARTIS AGNov 11, 2024HAMM&WITTKOPP PATENTANWALTE PARTMBB
EP3474820Glp-1 Compositions And Uses ThereofNOVO NORDISK A/SNov 7, 2024SANDOZ AG
EP3474820Glp-1 Compositions And Uses ThereofNOVO NORDISK A/SNov 6, 2024MAIWALD GMBH
EP3866765Injectable Long-Acting Naltrexone Microparticle CompositionsPURDUE RESEARCH FOUNDATIONNov 6, 2024ALKERMES PHARMA IRELAND LIMITED
EP2395968Pharmaceutical Composition Comprising Glucopyranosyl Diphenylmethane Derivatives, Pharmaceutical Dosage Form Thereof, Process For Their Preparation And Uses Thereof For Improved Glycemic Control In A PatientBOEHRINGER INGELHEIM INTERNATIONAL GMBHOct 17, 2024STADA ARZNEIMITTEL AG

To stay ahead in the competitive Form Specific Drugs industry, companies are constantly innovating. Here are the top patents facing oppositions in the Form Specific Drugs industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Patent NumberGrant DateTitleApplicantTotal Oppositions
EP2425821May 10, 2017Pharmaceutical Preparation Containing Oxycodone And NaloxoneMUNDIPHARMA AB21
EP2425824May 10, 2017Pharmaceutical Preparation Containing Oxycodone And NaloxoneMUNDIPHARMA PHARMACEUTICALS S.L.20
EP2395968Jan 17, 2024Pharmaceutical Composition Comprising Glucopyranosyl Diphenylmethane Derivatives, Pharmaceutical Dosage Form Thereof, Process For Their Preparation And Uses Thereof For Improved Glycemic Control In A PatientBOEHRINGER INGELHEIM INTERNATIONAL GMBH18
EP3246021Nov 13, 2019Apixaban FormulationsBRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMITED COMPANY12
EP3725778Aug 18, 2021Formulations Of EnzalutamideMEDIVATION PROSTATE THERAPEUTICS LLC11
EP3395339Dec 11, 2019Rapid Dissolution Formulation Of A Cinacalcet HclAMGEN11
EP2949335Jan 4, 2017Low Frequency Glatiramer Acetate TherapyYEDA RESEARCH & DEVELOPMENT COMPANY, LTD.11
EP3251660Oct 16, 2019Apixaban FormulationsBRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMITED COMPANY10
EP2791160Mar 2, 2022Modified Nucleoside, Nucleotide, And Nucleic Acid CompositionsMODERNATX, INC.10
EP2228064Dec 11, 2019Pharmaceutical Composition Containing Glycopyrrolate And A Beta2 Adrenoceptor AgonistNOVARTIS AG10